Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qufeng Huoxue is a Traditional Chinese Medicine (TCM) herbal formula developed by researchers at Zhongshan Hospital, Fudan University, specifically for the management of chemotherapy-induced peripheral neuropathy (CIPN) in patients with lung cancer. The formula is designed to "expel wind" (Qufeng) and "activate blood" (Huoxue), addressing the TCM pathogenesis of CIPN, which involves Qi deficiency and blood stasis. Clinical studies conducted at Zhongshan Hospital suggest that Qufeng Huoxue can significantly alleviate symptoms such as numbness, pain, and temperature sensitivity in the extremities of patients receiving neurotoxic chemotherapy, such as platinum-based agents or taxanes. Its therapeutic effects are attributed to its ability to improve local blood flow, reduce the levels of pro-inflammatory cytokines like TNF-alpha and IL-6, and enhance the expression of neurotrophic factors such as Nerve Growth Factor (NGF), thereby protecting peripheral nerves from oxidative damage and promoting axonal repair.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qufeng Huoxue.